Delivery Order SPE2DB25D9348-SPE2DB25FNMRX

Award Date 3/19/25
Potential Completion Date 4/9/25
Potential Value $82K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $82,041.50 contract is for the delivery of 4,566,940,918 units of the pharmaceutical product Keytruda (100 mg/4 ml vial) with a period of performance through February 3, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $82,041.50 contract is for the delivery of 4,567,268,549 units of the oncology medication Keytruda (100 mg/4 ml vial) with a performance period ending on March 4, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program,...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The $24,568.74 contract is for the delivery of 4,567,603,209 units of Keytruda 100 mg/4 ml vial (4 ml) to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the issuance...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $77,505.20 contract is for the delivery of 4,560,538,361 units of Keytruda 100 mg/4 ml vial (4 ml) to support the recurring medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) Medical Supply Chain division to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract, valued at $40,142.85, is for the delivery of Keytruda 100 mg/4 ml vials to support the recurring medical supply needs of military health facilities. The contract has a completion date of June 25, 2024. DMS Pharmaceutical Group holds a larger indefinite delivery...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $40,142.85 firm fixed-price contract is for the supply of Keytruda 100 mg/4 ml vial. The contract has an ultimate completion date of July 3, 2024. DMS Pharmaceutical Group holds a single-award indefinite delivery contract (IDC) with the DLA, valued at up to $499,999,999, which allows the agency to...
The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Keytruda (pembrolizumab) 100 mg/4 mL vials. The contract, valued at $80,218.40, has an ultimate completion date of October 9, 2024. This delivery order is part of a larger indefinite delivery contract (IDC) between DMS Pharmaceutical Group and DLA under the SPE2DB program, which has a ceiling value...
This federal contract award to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, is a delivery order valued at $120,428.55 to provide 4,566,597,117 units of Keytruda 100 mg/4 ml vial. The contract is a firm fixed-price award from the Defense Logistics Agency (DLA), a defense agency, and has an ultimate completion date of December 20, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $81,507.72 and covers the delivery of Keytruda 100 mg/4 ml vials to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business located in Park Ridge, Illinois. The $80,285.70 contract is for the provision of 4,566,808,579 units of Keytruda 100 mg/4 ml vial (4 ml) to support the medical supply needs of military healthcare facilities. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables...
  • SPE2DB25D9348
    Indefinite Delivery Contract
  • SPE2DB25D9348-SPE2DB25FNMRX
    Delivery Order

This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is valued at $82,041.50 and covers the delivery of 4,567,666,506 units of the drug Keytruda (100 mg/4 ml vial) with an ultimate completion date of April 9, 2025.

DMS Pharmaceutical Group Inc. is a key supplier in the federal pharmaceutical supply chain, providing a comprehensive range of pharmaceutical products and medical supplies to the Department of Defense (DoD). The company holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to issue firm fixed-price delivery orders for a wide variety of pharmaceutical items to support the medical needs of military health facilities worldwide. This specific delivery order is not associated with any set-aside designations, allowing DMS Pharmaceutical Group to leverage its woman-owned small business status to secure direct federal awards across multiple product categories.

Generated 6/18/25, 10:43 AM